A proposed primary prevention trial (Pre-POINT) [123] aims to address this issue of disease stage by intervening with oral or nasal insulin in children genetically predisposed to T1D, before the appearance of the first signs of β-cell autoimmunity (i.e., in children who have not yet developed IAA). Here, INS is linked to type 1 diabetes mellitus.